The Paper on Indian Pharma Industry – Quest for Global Leadership gives reasons for this growth, emphasising that indigenous pharma market is expected to be largely driven by new product launches, especially new branded drugs by foreign firms in next 4 years. The growth rate thus is likely to reach its peak by 2008-09, after which it may stagnate with a few new product launches, adds ASSOCHAM & Cygnus Paper.

Between 2000 to 2005, domestic pharma industry grew at an CAGR of about 9.5% and touched the market size at US$ 5.13 billion by March 2005.  However, towards March 2006, the growth rate jumped to 11% to hit the market size of US$ 5.7 billion, further adds the Paper, forecasting that it will hover around 13.6% between 2006-10 to take up domestic pharma market size at US$ 9.48 billion by 2010.

The Paper points out that indigenous pharma market in value terms accounts for 1% of global pharmaceutical market and 8% in volume terms.  Market growth before 2005 of domestic pharma industry was primarily driven by a number of new product launches by both Indian and foreign company.  The Indian market started to attract a number of foreign players with the implementation of product patent in January 2005. The FDI in pharma industry is estimated at US$ 172 million during 2005-06, recording a CAGR of 62.6% during the period beginning 2002-06.

According to estimates, contract research and manufacturing (CRAMS) market in India was valued at US$ 532.10 million in 2005, of which contract manufacturing accounted for 84% of the total market, while the remaining 16% was accounted by contract research excluding clinical trials.  Both the segments of CRAMS have registered a robust growth of over 40% in 2005 over the previous year.

According to ASSOCHAM President, Mr. Anil K Agarwal with recent CRAMS agreements, ASSOCHAM estimates that the clinical trial market in India will be US$ 200 million by 2007 and US$ 1 billion by 2010.  The contract manufacturing market is expected to reach US$ 900 million by 2010.

On clinical trials, the Paper comments that in 2005, the industry for clinical trials in India was US$ 100 million. This market is growing at an accelerated pace.  India offers a lot of advantages in the clinical trials domain such as cost advantage compared to Western countries.

On advantages offered by  India in CRAMS and clinical trials domain as per the Paper say “today the cost of hiring a medicinal chemist in the US is very high, approx. US$ 250,000-300,000 per year.  The US pharma industry employs roughly 50,000 chemists.  Indian discovery research outfits charge global pharma companies around US$ 60,000 per chemist which is roughly one-fifty of what the pharma companies pay abroad.  While it is difficult to pin down an average pay for chemists in India for doing a similar work, conservative estimates suggest it to be around Rs. 1 million per annum.  So it is a win-win situation the overseas pharma saves about 50% cost and the Indian company makes it about 50% margin.

Commenting on the future trends, the ASSOCHAM Chief said, that some of the major trends that are expected in the future include mergers and acquisitions in the industry; new product launches by MNCs and Indian companies; in-licensing of patented products by Indian companies to launch them in the Indian market and increase in the number of contract research organisations.

On increasing R&D spend of Indian companies, the Paper highlights “major pharmaceutical companies in India are the main R&D investor in the country.  The R&D spend (capital and current) of these major companies has grown at CAGR of 38% during the period 2000-01 to 2005-06.  In 2005-06, the R&D expenditure of 50 major companies totalled US$ 495.19 million growing at a rate of 26% over the previous year.  The higher growth rate is attributed to product patent implementation in the country in January 2005”.

According to its findings, the model of R&D investment by Indian shifting from crore process research to new drug development and novel drug delivery systems (NDDS). For instance, Ranbaxy has out-listed its NDDS to Bayer for the development of Cipro XR formulation.